CH653990A5 - Composto ad attivita antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche. - Google Patents

Composto ad attivita antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche. Download PDF

Info

Publication number: CH653990A5
Authority: CH; Switzerland
Prior art keywords: herpes; compound; pharmaceutical compositions; preparation; procedure
Prior art date: 1982-03-01

Application number

CH6269/82A

Other languages

English (en)

Italian (it)

Inventor

Vincentiis Leonardo De

Original Assignee

Ausonia Farma Srl

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1982-03-01

Filing date

1982-10-27

Publication date

1986-01-31

1982-10-27 Application filed by Ausonia Farma Srl filed Critical Ausonia Farma Srl

1986-01-31 Publication of CH653990A5 publication Critical patent/CH653990A5/it

Links

150000001875 compounds Chemical class 0.000 title claims description 13
238000000034 method Methods 0.000 title claims description 7
239000008194 pharmaceutical composition Substances 0.000 title claims description 5
238000002360 preparation method Methods 0.000 title claims description 3
230000000840 anti-viral effect Effects 0.000 title description 8
XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 claims description 13
UXQDWARBDDDTKG-UHFFFAOYSA-N tromantadine Chemical compound C1C(C2)CC3CC2CC1(NC(=O)COCCN(C)C)C3 UXQDWARBDDDTKG-UHFFFAOYSA-N 0.000 claims description 11
229960000832 tromantadine Drugs 0.000 claims description 11
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
206010019973 Herpes virus infection Diseases 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
208000001688 Herpes Genitalis Diseases 0.000 claims description 2
208000004898 Herpes Labialis Diseases 0.000 claims description 2
206010073938 Ophthalmic herpes simplex Diseases 0.000 claims description 2
206010067152 Oral herpes Diseases 0.000 claims description 2
238000001704 evaporation Methods 0.000 claims description 2
230000008020 evaporation Effects 0.000 claims description 2
201000004946 genital herpes Diseases 0.000 claims description 2
239000002798 polar solvent Substances 0.000 claims description 2
125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 claims 1
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 1
229910018828 PO3H2 Inorganic materials 0.000 claims 1
239000004480 active ingredient Substances 0.000 claims 1
241000700605 Viruses Species 0.000 description 13
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 9
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
230000000694 effects Effects 0.000 description 6
239000000243 solution Substances 0.000 description 5
229960005486 vaccine Drugs 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 4
238000010348 incorporation Methods 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
210000004027 cell Anatomy 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000003292 kidney cell Anatomy 0.000 description 2
239000002674 ointment Substances 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
238000011160 research Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
241000991587 Enterovirus C Species 0.000 description 1
206010015150 Erythema Diseases 0.000 description 1
208000010201 Exanthema Diseases 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
241001500351 Influenzavirus A Species 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
235000000434 Melocanna baccifera Nutrition 0.000 description 1
241001497770 Melocanna baccifera Species 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010046865 Vaccinia virus infection Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000011161 development Methods 0.000 description 1
230000018109 developmental process Effects 0.000 description 1
210000001840 diploid cell Anatomy 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000000921 elemental analysis Methods 0.000 description 1
231100000321 erythema Toxicity 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
201000005884 exanthem Diseases 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000002329 infrared spectrum Methods 0.000 description 1
238000003760 magnetic stirring Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
NINOYJQVULROET-UHFFFAOYSA-N n,n-dimethylethenamine Chemical group CN(C)C=C NINOYJQVULROET-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
-1 or sticks Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000009543 pathological alteration Effects 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
235000015320 potassium carbonate Nutrition 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
206010037844 rash Diseases 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
238000010992 reflux Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000010902 straw Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
208000007089 vaccinia Diseases 0.000 description 1
230000035899 viability Effects 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Communicable Diseases (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Pharmacology & Pharmacy (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

CH6269/82A 1982-03-01 1982-10-27 Composto ad attivita antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche. CH653990A5 (it)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT19901/82A IT1150209B (it)	1982-03-01	1982-03-01	Composto ad attivita'antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche

Publications (1)

Publication Number	Publication Date
CH653990A5 true CH653990A5 (it)	1986-01-31

Family

ID=11162187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH6269/82A CH653990A5 (it)	1982-03-01	1982-10-27	Composto ad attivita antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche.

Country Status (13)

Country	Link
JP (1)	JPS58164560A (fr)
BE (1)	BE894802A (fr)
CH (1)	CH653990A5 (fr)
DE (1)	DE3245188C2 (fr)
ES (1)	ES8308533A1 (fr)
FR (1)	FR2522327A1 (fr)
GB (1)	GB2115816A (fr)
GR (1)	GR77687B (fr)
IN (1)	IN155559B (fr)
IT (1)	IT1150209B (fr)
LU (1)	LU84443A1 (fr)
NL (1)	NL8204175A (fr)
PT (1)	PT75751B (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3767795A (en) *	1971-02-25	1973-10-23	Abbott Lab	Method for combating certain virus infection
US4052439A (en) *	1976-04-30	1977-10-04	Abbott Laboratories	Carboxylic esters of phosphonoacetic acid

1982
- 1982-03-01 IT IT19901/82A patent/IT1150209B/it active
- 1982-10-25 GR GR69622A patent/GR77687B/el unknown
- 1982-10-25 JP JP57188069A patent/JPS58164560A/ja active Pending
- 1982-10-26 ES ES516854A patent/ES8308533A1/es not_active Expired
- 1982-10-26 BE BE2/59880A patent/BE894802A/nl not_active IP Right Cessation
- 1982-10-27 PT PT75751A patent/PT75751B/pt unknown
- 1982-10-27 FR FR8217996A patent/FR2522327A1/fr active Granted
- 1982-10-27 CH CH6269/82A patent/CH653990A5/it not_active IP Right Cessation
- 1982-10-27 LU LU84443A patent/LU84443A1/fr unknown
- 1982-10-28 GB GB08230888A patent/GB2115816A/en not_active Withdrawn
- 1982-10-28 NL NL8204175A patent/NL8204175A/nl not_active Application Discontinuation
- 1982-10-29 IN IN1276/CAL/82A patent/IN155559B/en unknown
- 1982-12-07 DE DE3245188A patent/DE3245188C2/de not_active Expired

Also Published As

Publication number	Publication date
PT75751B (en)	1986-03-11
JPS58164560A (ja)	1983-09-29
DE3245188A1 (de)	1983-09-15
ES516854A0 (es)	1983-09-16
LU84443A1 (fr)	1983-06-13
PT75751A (en)	1982-11-01
IT8219901A0 (it)	1982-03-01
GR77687B (fr)	1984-09-25
DE3245188C2 (de)	1984-09-13
FR2522327A1 (fr)	1983-09-02
ES8308533A1 (es)	1983-09-16
BE894802A (nl)	1983-02-14
FR2522327B1 (fr)	1984-12-21
IT1150209B (it)	1986-12-10
NL8204175A (nl)	1983-10-03
IN155559B (fr)	1985-02-16
GB2115816A (en)	1983-09-14

Legal Events

Date	Code	Title	Description
1989-06-30	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
CA1329392C (fr)	1994-05-10	Derives imidazole et triazole, et agents antiviraux et radiosensiblisants en comportant
US6562861B1 (en)	2003-05-13	Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors
FI73682B (fi)	1987-07-31	Foerfarande foer framstaellning av antiviralt 9-(1,3-dihydroxi-2-propoximetyl)guanin samt mellanprodukt.
US4504469A (en)	1985-03-12	Vasotocin derivatives
IE51944B1 (en)	1987-04-29	Zanthates and their therapeutic use
ES2197632T3 (es)	2004-01-01	Procedimiento de preparacion de aloina por extraccion.
CH653990A5 (it)	1986-01-31	Composto ad attivita antivirale, procedimento per la sua preparazione e relative composizioni farmaceutiche.
FI78705C (fi)	1989-09-11	Foerfarande foer framstaellning av terapeutiskt anvaendbara bassalter av cyklofosfamidderivat.
CA2007785C (fr)	1996-09-03	1-[3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl] -2-thienyl]-3-phenyl-1-propanones et procede de preparation
US4657923A (en)	1987-04-14	Econazole-acexamic acid addition compound having antimycotic, cicatrizing and antiinflammatory activity
FI57589C (fi)	1980-09-10	Foerfarande foer framstaellning av blodtrycket saenkande 6-substituerade 3-karbetoksihydrazinopyridaziner
FI88502C (fi)	1993-05-25	Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 1-/3-(2-aminoetoxi)-2-tienyl/-3-fenyl-1-propanoner
CN114573651A (zh)	2022-06-03	一种n4-羟基胞苷脂质前药及其制备方法与应用
CN118406038B (zh)	2024-12-06	一种具有抗肿瘤活性的化合物及其制备方法和应用
WO2014167581A2 (fr)	2014-10-16	Procédé amélioré pour la préparation de promédicaments triptolides
CN117003766B (zh)	2024-02-02	一种抗流感病毒衍生物及其用途
CA1243682A (fr)	1988-10-25	Compose pharmaceutique d'addition entre l'econazole et l'acide acexamique
EP0080305A1 (fr)	1983-06-01	2'-Déoxyuridines à activité antivirale, leur préparation et emploi
KR810001818B1 (ko)	1981-11-16	1-설포닐-5(6)-치환된-벤즈이미다졸의 제조방법
ES2341982T3 (es)	2010-06-30	Uso de analogos de la amigdalina para el tratamiento de la psoriais.
KR810001896B1 (ko)	1981-11-20	1-설포닐-5(6)-치환된 벤즈이미다졸의 제조 방법
KR101007927B1 (ko)	2011-01-14	시부트라민-ｌ-카르니틴 다이술폰산염, 이의 제조방법 및 이를 포함하는 약제학적 조성물
JP2023552672A (ja)	2023-12-19	ヌクレオシド類似体の塩及びその結晶形、医薬組成物並びに用途
Balenović et al.	1954	Studies in the Muscarine Series. II Acetals of Betaine Aldehyde and Their Musoadnic Activity; Some Views on the Structure of Muscarine
WO2025237335A1 (fr)	2025-11-20	Sel pharmaceutiquement acceptable de dérivé de cucurbiturile, forme cristalline de celui-ci et son utilisation